Date: Oct 29, 2012 Author: press release Source: GlobeNewswire (
click here to go to the source)
CAMBRIDGE, MASS., Oct. 29, 2013 (GLOBE NEWSWIRE) --
Today, at the Company's annual User Group Meeting, Hepregen Corporation, leader in the development of next generation HepatoPac™ and HepatoMune™ cell-based assay products, announced the commercial launch of the Company's first application-oriented, monkey HepatoPac™ kits, designed specifically for use in metabolite identification and profiling. The kits contain one or more standard 24-well tissue culture plates containing micro-patterned monkey liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates remain fully functional for up to 35 days. Each of the kits provides customers with a plug-in-ready product that can be used to evaluate metabolite production in monkey liver cells.
Dr. Vincent Zurawski, Hepregen's chief executive officer stated, "This new monkey HepatoPac™ kit adds a fifth product for metabolite identification and profiling to Hepregen's growing application-directed product line. This monkey kit complements the recently introduced human, rat, human triple-donor and rat-human HepatoPac™ kits for metabolite identification and profiling."
About Hepregen Corporation
Hepregen Corporation is the undisputed leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and pharmaceutical, biotherapeutic and diagnostic product development. The Company's micro-liver HepatoPac™ and HepatoMune™ cell-based assays are driving a paradigm shift in drug development. The utility of Hepregen's human, rat, monkey, dog, and multi-species/multi-donor HepatoPac™ and HepatoMune™ products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Ventures with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications.
A photo accompanying this release is available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=21886
Hepregen Corporation
Katherine Sydney Cook
Tel: 1-781-391-0205 x108
Email:
www.hepregen.com
